Mini-Plenary Sessions
Wednesday, October 22
8:30 a.m. - NOON
 Health Care Sector Mini-Plenary
Session 1: Feeding the Pipeline, Part IX
Ed Saltzman'
s Feeding the Pipeline presentation series began in 2000, and has become a much anticipated LES Annual Meeting event for the Health Care Sector. Current issues and trends are reflected in this forward-looking talk for those in L&BD and M&A responsible for devising corporate growth strategies and tactics amidst a well recognized innovation deficit and public and private funding challenges. Join us for what will surely be another highlight of this meeting.
Speaker: Ed Saltzman, President, Defined Health
Session 2: Pharma'
s New Follow-On Strategy
The Health Care Sector welcomes back Roger Longman to the podium to speak on a new topic. Roger, a noted industry visionary, will provide us with insight gained from his career closely monitoring our industry, which he frequently writes about in various publications including IN VIVO and START-UP magazines.
As he sees it, biotech investors currently see their best exits through M&A, yet activities in this area have been unpredictable and less buoyant than expected – largely because drug companies haven'
t yet felt the necessity of upping their external spend on pipeline replenishment. Still, generics and a coming cash-flow crunch will force drug companies, which have been spending their money on shareholders as much as on pipelines, to choose between the two. He suggests the quickest solution to pipeline problems is to imitate biotechs by developing or buying biotech products and technologies. These technologies allow Big Pharma to do with biologics what they used to do with small molecules: create fast-followers. Except, according to Roger, there'
s far more competition this time around.
Speaker: Roger Longman, Managing Partner,Windhover Information Inc.
Moderators:
Sector Chair, Jake Schaible, President, Toscana Ventures, Inc.
Sector Chair Elect, Mark Nawacki, Vice President, Business and Corporate Development, Paladin Labs, Inc.
 High Technology Sector Mini-Plenary
Global Patenting and Intellectual Property Transaction Trends
Global markets coupled with greater respect for IP rights worldwide has driven increased investment in IP and therefore transactions. Global investment in IP is being funded directly by companies and private equity groups, which are funded by companies, institutions and individuals. This trend has increased the pressure on licensing and business development professionals to produce greater returns for their organizations. This session will begin with a review of the global trends in patenting and transactions, followed by a panel discussion representing the experience of global companies based in Asia, Europe and the U.S.
Moderator: David Yurkerwich, Vice President, CRA International
Panelists:
John Han, Vice President, Patent Development, Ericsson AB
Ho Lee, Senior Manager, Intellectual Property Center, Chief Technology Officer, LG Electronics (Invited)
Marshall Phelps, Corporate Vice President and Deputy General Counsel, Microsoft Corporation
 Consumer Products Sector Mini-Plenary
Protecting Brand Equity in a Global Economy
Part I will focus on how to manage brand licensing in a flat world. Success in brand licensing in an increasingly complex global market requires skills in alliance management, increasing diligence, and advanced approaches to enterprise risk management. This session will include discussion on licensee selection criteria, licensee management, ensuring product quality and social responsibility.
Part II will focus on "
Innovation Fatigue"
, when a company'
s employees grow weary of innovation. It will highlight key "
fatigue factors"
and offer guidance on how to avoid or overcome them. Governance, advisors, looking beyond patents, and integrating marketing strategies with the intellectual asset story to prepare for the right connections with targeted partners will be discussed.
Kimberly Billoni, Chief Executive, Society of Product Licensors Committed to Excellence
Carlos Coroalles, Vice President, Licensing, Jarden Consumer Solutions
Malcolm Denniss, SGS Group,World Class Testing and Certification Company
Mukund Karanjikar, Chevron Technology Ventures
Jeffrey Lindsay, Director of Solution Development, Innovationedge
Cheryl Perkins, Founder and President, Innovationedge
Emily Stone, Owner, Stone Group, Brand Licensing Agency
Corinne Sukiennik, Former Director,Global Licensing, Kimberly-Clark Corporation
 Chemicals, Energy & Materials Sector Mini-Plenary
Open Innovation: Insight into Models, Process and Issues in Collaborative Research & Development in the Global World
(CEM Sector, IUGI Sector, Licensing Office and Structure Management Committee, Strategic Alliances Committee)
We live in an ever changing, ever smaller world. Open Innovation processes and strategies have been adopted by companies looking to maintain their global competitive advantage by innovating quickly and efficiently. Specifically, research and development must keep pace with the increasing demand for innovation by seeking outside sources through partnering and collaboration. The Open Innovation approach provides the opportunity to fill technical and other gaps by aggregating the best talent and ideas from a particular industry. These outside sources may include crossing geographic boundaries to seek out foreign partners and incorporate companies, universities and government research. However, the complexity of bringing multiple organizations together to collaborate can be challenging. This mini-plenary will focus on the challenges of selecting the right partner and ways of getting the deal done, while addressing issues relating to deal structure, risk distribution, allocation of ownership or rights to intellectual property, and managing the relationship throughout the partnership. Come and learn proven processes and strategies for Open Innovation that facilitate the search for partners and deal with the complex IP issues. A variety of real life examples and case studies will be provided to support the key points and demonstrate the models and approaches.
Eugene Buff, Consulting Director, yet2.com, Inc.
Ed Carreras, Attorney, Woodcock Washburn LLP
John Cronin, Managing Director, ipCapital Group
Phyl Speser, Chief Executive Officer, Foresight Science & Technology
Bruce Story, Senior Director, Intellectual Capital, Dow Chemical Company
 Industry-University-Government Interface Mini-Plenary
Sponsored & Collaborative Research: IP Demands in Deals Between Universities/Research Institutes and Industry
This session will focus on the intellectual property interests of universities/ research institutions and industry in negotiating and administering sponsored and collaborative research agreements. The panel includes speakers with substantial experience in sponsored and collaborative research agreements from the perspectives of the university, research institution, high tech, and outside counsel. The session will cover the extent to which intellectual property rights are retained by the university/research institution and granted to the research sponsor; sharing licensing revenues; the right to the free publication of results; and universities'
/ research institutions'
interests in making inventions available under conditions that will promote their effective development and utilization in the public interest.
Additionally, the following topics will be discussed: general philosophy; who owns the IP; IRS issues; background rights; publication; patent prosecution; patent enforcement; development & commercialization; and other issues such as faculty consulting (pitfalls / benefits; impact on collaboration & relationship); research tools/MTA (how the distribution of research materials is handled); valuing the "
outcome"
of sponsored or collaborative research; timing (before timing or after research) and expectations; and preferences (how research institutions and companies choose partners or collaborators).
Moderator:
Thomas Meagher, Partner, Duane Morris LLP
Steven Ferguson, Director, Division of Technology Development and Transfer Office of Technology Transfer, National Institutes of Health
Peter Kramer, Senior Director, External Science and Technology, Bristol-Myers Squibb Company
John Ritter, Director, Princeton University
|
